CAPN2 and prostate cancer: Furthermore, calpain 2 can also cleave AR to generate a truncated, functional AR without ligand-binding domain in androgen-sensitive prostate cancer cells, which enables cancer cell adaptation to androgen-independent growth and proliferation during androgen-deprivation treatment (7).